Optoceutics
Optoceutics develops and sells EVY LIGHT, a patented 40Hz light and sound stimulation device marketed to families and caregivers of patients with Alzheimer's, dementia, and Mild Cognitive Impairment. It is sold direct-to-consumer via optoceutics.com with an optional mobile app.
- Company typePrivate
- Founded2018
- HeadquartersKongens Lyngby, Denmark
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Optoceutics does
Optoceutics is a privately held consumer wellness company founded in 2018 that develops and sells the EVY LIGHT device, a non-invasive 40Hz light and sound stimulation product marketed to families and caregivers of individuals with Alzheimer's disease, dementia, and Mild Cognitive Impairment (MCI). The technology is grounded in gamma wave entrainment: 40Hz light is delivered via the hardware device and 40Hz sound is delivered through the optional EVY INSIGHT mobile app (iOS and Android), producing a dual-pathway multi-sensory stimulation protocol. A key proprietary element is the patented Invisible Spectral Flicker (ISF) technology, which reduces the perceived flicker of 40Hz strobe light and enables use during everyday activities such as reading, watching TV, or conversing. The product is positioned as an FDA low-risk general wellness device and is not subject to FDA medical-device regulation.
The company was co-developed with UC Berkeley and the Technical University of Denmark (DTU) and is supported by a scientific advisory board that includes prominent Alzheimer's researchers. Optoceutics sells EVY LIGHT directly to consumers through its optoceutics.com storefront with a 90-day money-back guarantee and free shipping, and has launched a healthcare provider program targeting clinicians who serve dementia patients. Revenue mechanics are anchored on one-time hardware device sales, with the EVY INSIGHT app potentially layered as a recurring software component (pricing is not publicly disclosed).
The company is headquartered in Berkeley, California, with operational ties to Kongens Lyngby, Denmark, and reports 11-50 employees. Disclosed external capital is limited to approximately $82K raised in 2019 from EISMEA and SkyDeck Berkeley, and no subsequent funding rounds, mergers, acquisitions, or leadership changes have been disclosed in the available source data.
Optoceutics firmographics
Firmographics- Name
- Optoceutics
- Legal name
- Optoceutics
- Website
- https://optoceutics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Optoceutics develops and sells EVY LIGHT, a patented 40Hz light and sound stimulation device marketed to families and caregivers of patients with Alzheimer's, dementia, and Mild Cognitive Impairment. It is sold direct-to-consumer via optoceutics.com with an optional mobile app.
- Ownership category
- akta.pro rank
Optoceutics industry classification
Industry- Product category
- Brain Wellness Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)
- akta.pro secondary industry
- Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH)
Keywords
Where Optoceutics is headquartered
LocationHeadquarters
- HQ city
- Kongens Lyngby
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Optoceutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- EVY LIGHT Device Sales: Sale of the EVY LIGHT hardware device, a brain wellness device that delivers 40Hz light stimulation. The device is sold directly through the company's e-commerce platform with a 90-day money-back guarantee.
- EVY INSIGHT App (Optional): The companion mobile app provides 40Hz sound stimulation, brightness customization, and usage tracking. The app is optional and available for Apple and Android devices, potentially offered as an add-on or included with device purchase.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Optoceutics product offering
Product offeringCore offering
Optoceutics sells the EVY LIGHT, a consumer-grade brain wellness device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology, complemented by the optional EVY INSIGHT mobile app that adds 40Hz sound therapy, brightness control, and usage tracking. The product is sold directly to consumers (primarily families and caregivers of individuals with Alzheimer's, dementia, or MCI) through the company's e-commerce storefront with a 90-day money-back guarantee.
Product overview
Optoceutics offers a unified consumer wellness solution centered on the EVY LIGHT device — a 40Hz light stimulation device featuring patented Invisible Spectral Flicker (ISF) technology — complemented by the EVY INSIGHT mobile app (iOS and Android) which adds app-based 40Hz sound stimulation, brightness control, and usage tracking. The company operates a direct-to-consumer model with a 90-day money-back guarantee and serves individuals with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI) as a general wellness product (not a medical device).
Differentiator
Problem solved
Functional benefit
Brands
- EVY: General wellness device using 40Hz light and sound stimulation for brain health, targeting families living with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI)
- EVY LIGHT
- EVY INSIGHT
Products and services
- EVY LIGHT EVY LIGHT is a general wellness hardware device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology to support cognitive health in individuals living with Alzheimer's, dementia, or Mild Cognitive Impairment (MCI). It is sold directly to families and caregivers through the company's e-commerce site with one-button simple operation.
- EVY INSIGHT App
Quantifiable outcome
- 95% of families report improvements in sleep, memory, focus, energy, and mood within 5 weeks
- +4 more outcomes
Companies that use Optoceutics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Optoceutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature4 records
Optoceutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- University of California, BerkeleycoreEVY was developed in collaboration with UC Berkeley. The university partnership provides scientific credibility and research infrastructure for the 40Hz light therapy technology.
- Technical University of Denmark (DTU)coreEVY was developed in collaboration with DTU (Danish Technical University). The international academic partnership contributed to the research and development of the 40Hz therapy technology.
- MasonicareminorMasonicare, a senior living and memory care community, conducted a 6-week independent pilot study of EVY. Results showed caregivers saw residents improve across all five tracked areas: sleep, mood, focus, energy, and memory, and caregivers reported the device eased their daily workload. Published as a white paper.
- Scientific Advisory BoardcoreThe scientific advisory board includes Dr. Jeffrey Cummings (Prof., MD, ScD, Neurology), Dr. Henrik Zetterberg (Prof., MD, Neurochemist), Dr. William Jagust (Prof., MD, Alzheimer's Expert), Dr. Silke Kern (Prof., PhD, MD), and Dr. Jan Pedersen (Biophysicist, PhD, MSc). These advisors ensure EVY is backed by the latest cognitive health research.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Optoceutics competitors and assessment
Company assessmentOthers
- Alzheimer's Association: The Alzheimer's Association is the dominant US patient advocacy, research funding, and provider-credentialing body for Alzheimer's care. While not a commercial peer, it shapes the recommendation channels and clinical credibility that Optoceutics' provider program depends on.
Broad incumbents
- Cala Health: Cala Health markets FDA-cleared wearable neuromodulation therapy (TAPS) for essential tremor and is expanding into other neurological indications. It represents a broader incumbent in wearable neurostimulation with regulatory and reimbursement muscle Optoceutics lacks.
- NeuroPace: NeuroPace commercializes the FDA-approved RNS system for epilepsy, a brain neuromodulation platform. It is a broader incumbent in implanted/responsive neurostimulation relevant to Optoceutics' long-term aspiration of clinical-grade brain stimulation.
Emerging players
- Cognivue: Cognivue develops FDA-cleared computerized cognitive assessment tools used in primary care to detect early cognitive decline. It is comparable to Optoceutics as an enabler in the early-detection and management pathway for Alzheimer's and MCI patients, though in diagnostics rather than therapy.
- LumosTech: LumosTech (formerly Axon Labs) is developing light-based cognitive therapy devices targeting cognitive impairment and circadian rhythm disorders. It is comparable to Optoceutics as a light-modality neurostimulation startup addressing adjacent cognitive and sleep indications.
- BrainBright: BrainBright is a Nordic startup offering light/sound-based brain stimulation devices for cognitive performance and dementia support. It is comparable to Optoceutics on 40Hz-style consumer neurostimulation and geographically close (Nordics) to Optoceutics' Danish roots.
- Posit Science (BrainHQ): Posit Science sells BrainHQ, a cognitive training software platform targeting healthy aging and dementia risk reduction. It overlaps Optoceutics on the non-pharmacological cognitive-wellness value proposition, with a software-first, recurring-revenue model that contrasts Optoceutics' hardware approach.
Direct peers
- Neuronix: Neuronix develops neurostimulation-based therapies (neuroAD) for Alzheimer's disease, combining transcranial magnetic stimulation with cognitive training. It competes with Optoceutics in the non-pharmacological Alzheimer's intervention space, though via a different stimulation modality.
- Cognito Therapeutics: Cognito Therapeutics is developing a 40Hz non-invasive neuromodulation therapy for Alzheimer's disease — the same core modality Optoceutics commercializes via EVY LIGHT. Cognito is running the landmark HOPE trial that supplies the headline efficacy figures Optoceutics cites, making it the most direct clinical and competitive peer.
- Vielight: Vielight sells consumer and clinical photobiomodulation (PBM) devices that deliver intranasal and transcranial light stimulation, including 40Hz-capable models. It overlaps Optoceutics on light-based neuromodulation for brain health, with a similar direct-to-consumer wellness positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Optoceutics social profiles
Digital presenceOptoceutics compliance and trust
Trust signalCompliance1 record
Optoceutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optoceutics leadership team
Management profileNumber of profiles
Profiles2 records
Optoceutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optoceutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optoceutics
What does Optoceutics do?
Optoceutics sells the EVY LIGHT, a consumer-grade brain wellness device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology, complemented by the optional EVY INSIGHT mobile app that adds 40Hz sound therapy, brightness control, and usage tracking. The product is sold directly to consumers (primarily families and caregivers of individuals with Alzheimer's, dementia, or MCI) through the company's e-commerce storefront with a 90-day money-back guarantee.
Is Optoceutics a public or private company?
Optoceutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Optoceutics founded?
Optoceutics was founded in 2018. It employs 11 to 50 people.
Where is Optoceutics based?
Optoceutics is headquartered in Kongens Lyngby, Denmark, in the Europe region.
How does Optoceutics make money?
Two revenue lines are on record. EVY LIGHT Device Sales are the primary driver. The others are EVY INSIGHT App (Optional).
Who are Optoceutics's main competitors?
Alzheimer's Association is listed as an others. Broad incumbents are Cala Health and NeuroPace. Emerging players are Cognivue, LumosTech, BrainBright and Posit Science (BrainHQ). Direct peers are Neuronix, Cognito Therapeutics and Vielight.
Does Optoceutics have an API?
No public API is recorded for Optoceutics.
What industry is Optoceutics in?
Optoceutics's product category is Brain Wellness Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of HSABAEAH, Cognitive Stimulation & Reminiscence Therapy (Non-Clinical). Its NAICS code is 334510 and its SIC code is 3845.